Category Press Releases

Fujirebio

Fujirebio and Sysmex Launch Sales Partnership to Expand Dementia Testing Solutions

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and…

Read MoreFujirebio and Sysmex Launch Sales Partnership to Expand Dementia Testing Solutions
Diagnostic

China’s NMPA Approves Promega’s MSI Detection Kit as a Companion Diagnostic for KEYTRUDA®

China NMPA Approves Promega MSI Detection Kit as Companion Diagnostic for KEYTRUDA® The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is intended…

Read MoreChina’s NMPA Approves Promega’s MSI Detection Kit as a Companion Diagnostic for KEYTRUDA®
FDA

FDA Approves Hologic’s Aptima® HPV Assay for Primary Screening, Expanding Cervical Health Offerings

Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio Hologic, Inc. announced today that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic’s human papillomavirus (HPV) test is the only FDA-approved mRNA-based…

Read MoreFDA Approves Hologic’s Aptima® HPV Assay for Primary Screening, Expanding Cervical Health Offerings
Stelo Adds

Stelo Adds New Smart Meal Logging Features to Strengthen Personal Glucose Management

Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management Dexcom, Inc. the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their…

Read MoreStelo Adds New Smart Meal Logging Features to Strengthen Personal Glucose Management

Nubeqa™ (Darolutamide) Secures Third Approval in China for Treatment of Advanced Prostate Cancer in Men

Nubeqa™ (Darolutamide) Gains Third Approval in China for Treatment of Advanced Prostate Cancer in Men The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in combination with androgen deprivation therapy (ADT) for…

Read MoreNubeqa™ (Darolutamide) Secures Third Approval in China for Treatment of Advanced Prostate Cancer in Men

Bio-Techne Launches Fully Defined Synthetic Solution to Expand 3D Stem Cell and Organoid Culture Portfolio

Bio-Techne Broadens 3D Stem Cell and Organoid Culture Offerings with a Fully Defined, Synthetic Matrix Alternative Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the launch of Cultrex™ Synthetic Hydrogel, a fully defined…

Read MoreBio-Techne Launches Fully Defined Synthetic Solution to Expand 3D Stem Cell and Organoid Culture Portfolio

AstraZeneca Expands Weight Management Portfolio via Collaboration with CSPC Pharmaceuticals

AstraZeneca Expands Weight Management Portfolio via Collaboration with CSPC Pharmaceuticals AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across…

Read MoreAstraZeneca Expands Weight Management Portfolio via Collaboration with CSPC Pharmaceuticals

Glaukos Announces FDA Approval of NDA Supplement Permitting Re-Administration of iDose® TR

Glaukos Announces FDA Approval for Re-Administration of iDose® TR Glaukos Corporation, an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration…

Read MoreGlaukos Announces FDA Approval of NDA Supplement Permitting Re-Administration of iDose® TR
Teva

Will Forte Partners with Teva for “Honestly HD” Campaign to Raise Awareness About Huntington’s Disease

Will Forte Partners with Teva to Launch “Honestly HD”—A Candid Conversation About Huntington’s Disease Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a partnership with actor, comedian and advocate, Will Forte, to…

Read MoreWill Forte Partners with Teva for “Honestly HD” Campaign to Raise Awareness About Huntington’s Disease